Compare iShares MSCI Hong Kong ETF (EWH) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Repligen Corporation Common Stock — how do they compare? iShares MSCI Hong Kong ETF trades at $21.92 (market cap $1.21B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 9.3× iShares MSCI Hong Kong ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 63 Days and Repligen Corporation Common Stock for 0 Days on average.
| EWH | RGEN | |
|---|---|---|
Market Cap | $1.21B | $11.31B |
Volume | 9,334,618 | 1,216,919 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $194.57 |
52-Week Low | $20.92 | $102.87 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH (iShares MSCI Hong Kong ETF) trades at $22.35, up 1.78% today, but faces bearish technical signals with moving averages indicating selling pressure. The ETF tracks Hong Kong stocks, which have experienced significant volatility amid US-China tensions and Federal Reserve policy concerns. Recent news highlights the Hang Seng Index's 11% decline from yearly highs, reflecting investor caution toward Chinese markets.
The outlook remains cautious due to geopolitical risks and Hong Kong's economic challenges. While technical oscillators show neutral momentum, institutional selling (Empowered Funds reduced holdings by 70% in Q3 2026) signals bearish sentiment. Key risks include US-China relations and Fed policy, but potential rebounds hinge on regional stability and tech sector recovery.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
